Erada Technology Alliance specializes in developing innovative rapid diagnostic solutions aimed at the early detection and accurate diagnosis of infectious diseases, with a particular focus on malaria. The company serves global healthcare markets, including public health organizations, hospitals, and research institutions. Erada's business model revolves around the development and commercialization of cutting-edge diagnostic technologies that can identify asymptomatic and symptomatic infections, thereby supporting vaccination programs and further vaccine development. Revenue is generated through the sale of diagnostic devices and related services. The company is committed to global, large-scale screening initiatives to eradicate detectable and treatable infectious diseases.

Keywords: rapid diagnostics, infectious diseases, malaria detection, asymptomatic infection, symptomatic diagnosis, healthcare technology, global screening, vaccine support, public health, diagnostic devices.